Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06154772
Other study ID # 27/09/2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 27, 2023
Est. completion date June 27, 2024

Study information

Verified date December 2023
Source Ataturk University
Contact Gülcan Bahçecioglu Turan
Phone 05065576086
Email glcnbah@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to investigate the effect of color therapy on quality of life, anxiety and fatigue levels in patients with Parkinson's disease.


Description:

Color Therapy aims to balance and heal our body's energy centers using the seven color spectrum, which helps to promote our body's own healing process. Thus good health and well-being is achieved through the balance of all these energies. Color therapy basically consists of color and character analysis with name, color therapy with chakras, programming of the pendulum, chakras and color application, color application with water, color application with colored light device.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 27, 2024
Est. primary completion date April 27, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Having been diagnosed with Parkinson's disease for at least 6 months, - Those who have not taken sleeping pills or sedative drugs, - Not having undergone brain stimulation surgery, - Do not have a physical illness or cognitive disability that would prevent them from understanding the education provided, and do not have a diagnosis of a psychiatric disease, - According to the Parkinson's Fatigue Scale, the scale score is >8 - The patient or someone living in the same house with the patient is literate, - Patients have no vision problems. Exclusion Criteria: - Parkinson patients who did not agree to participate in the research

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Color Therapy
Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.

Locations

Country Name City State
Turkey Firat University Elazig

Sponsors (1)

Lead Sponsor Collaborator
Ataturk University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of Life Scale (SF36) It was developed to measure the quality of life in people with physical diseases. It is measured in 8 dimensions and 36 items: physical function, physical role difficulty, emotional role difficulty, viability, mental health, social functionality, pain, and general health perception. At the end of Color Therapy (therapy 9 times in total in 3 months)
Primary Beck Anxiety Inventory (BAI) It consists of 21 questions and a minimum score of 0 and a maximum score of 3 is obtained from each question. As a result of the answers to all questions, all answers are summed up and a total score is obtained. In the evaluation phase, the presence and level of depression is interpreted in line with the meanings expressed by the score ranges. In the evaluation, 0-9 point range defines the presence of minimal depressive symptoms, 10-16 point range defines the presence of mild depressive symptoms, 17-29 point range defines the presence of moderate depressive symptoms and 30-63 point range defines the presence of severe depressive symptoms. A score of 17 and above indicates a level of depression that may require treatment. At the end of Color Therapy (therapy 9 times in total in 3 months)
Primary Parkinson's Fatigue Scale (PYO-16) It consists of 16 items, with 5 responses for each item (1=strongly disagree, 5=strongly agree). The result evaluation can be done in two different ways. The total value is calculated as the average of the response to all items (value range 1-5). Scores above the average "3.3" are considered tired. In the other rating option, 0 (actual response 1-3) and 1 (actual response 4-5) are scored, with a total value between 0-16. A total of 8 points and above is considered tired. In both methods, a higher value indicates a higher level of fatigue. At the end of Color Therapy (therapy 9 times in total in 3 months)
See also
  Status Clinical Trial Phase
Completed NCT06037590 - A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA® Phase 1
Recruiting NCT01537224 - Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information N/A
Withdrawn NCT04011449 - State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S N/A
Completed NCT02539446 - Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease N/A
Completed NCT00358189 - Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease N/A
Active, not recruiting NCT04606979 - tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease N/A
Completed NCT05119803 - The Relationship of Spine Posture and Mobility With Upper Extremity Functions in Parkinson's Patients
Not yet recruiting NCT02249715 - Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease N/A
Completed NCT01732653 - A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults N/A
Completed NCT03232996 - Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. N/A
Enrolling by invitation NCT04566341 - Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
Active, not recruiting NCT04978597 - Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) Phase 3
Recruiting NCT06116084 - Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine N/A
Recruiting NCT05830396 - GRoningen Early-PD Ambroxol Treatment Phase 2/Phase 3
Not yet recruiting NCT05379062 - Choral Singing for Patients With Parkinson's N/A
Completed NCT02071823 - Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules Phase 1
Recruiting NCT03558568 - The Effect of Deep Brain Stimulation on Facial Expressions. N/A
Enrolling by invitation NCT05596201 - Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease
Recruiting NCT04181918 - Action Observation Treatment in Parkinson's Patients N/A
Completed NCT02305277 - Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers Phase 1